

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

VOLUNTARY ANNOUNCEMENT

LEGEND BIOTECH WILL PRESENT NEW DATA ON CARVYKTI FOR PATIENTS WITH MULTIPLE MYELOMA AT 2025 ASCO AND EHA ANNUAL MEETINGS

This is a voluntary announcement made by GenScript Biotech Corporation (the “**Company**”).

Legend Biotech Corporation (“**Legend Biotech**”), an associate of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the “**SEC**”) on 22 May 2025 (New York time) (before trading hours on 23 May 2025 in Hong Kong) and announced that new data from the CARTITUDE Clinical Development Program evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma will be presented at the 2025 American Society of Clinical Oncology (“**ASCO**”) Annual Meeting and the 2025 European Hematology Association’s (“**EHA**”) Congress. For details, please refer to the press release as published on Legend Biotech’s website available at <https://investors.legendbiotech.com/press-releases>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
GenScript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 23 May 2025

*As at the date of this announcement, the executive Directors are Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Mr. Jiange Meng (“**Mr. Robin Meng**”), Ms. Ye Wang (“**Ms. Sally Wang**”) and Dr. Li Zhu; the non-executive Director is Dr. Luquan Wang (“**Dr. Larry Wang**”); and the independent non-executive Directors are Mr. Zumian Dai (“**Mr. Edward Dai**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Mr. Yiu Leung Andy Cheung, Dr. Chenyang Shi (“**Dr. Victor Shi**”), Dr. Alphonse Galdes, Dr. Ross Grossman, and Dr. John Quelch.*